Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth.

Oshima T, Niwa Y, Kuwata K, Srivastava A, Hyoda T, Tsuchiya Y, Kumagai M, Tsuyuguchi M, Tamaru T, Sugiyama A, Ono N, Zolboot N, Aikawa Y, Oishi S, Nonami A, Arai F, Hagihara S, Yamaguchi J, Tama F, Kunisaki Y, Yagita K, Ikeda M, Kinoshita T, Kay SA, Itami K, Hirota T.

Sci Adv. 2019 Jan 23;5(1):eaau9060. doi: 10.1126/sciadv.aau9060. eCollection 2019 Jan.

2.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.

3.

Inhibition of USP10 induces degradation of oncogenic FLT3.

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2.

4.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS.

Bioorg Med Chem. 2017 Feb 15;25(4):1320-1328. doi: 10.1016/j.bmc.2016.11.034. Epub 2016 Dec 7.

5.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

6.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD.

Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23.

7.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q.

Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13.

8.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q.

Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. Epub 2015 Jul 3. No abstract available.

9.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD.

Blood. 2015 May 14;125(20):3133-43. doi: 10.1182/blood-2014-12-615906. Epub 2015 Apr 1.

10.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.

Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, Neuberg D, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M.

Leukemia. 2015 Jul;29(7):1555-1563. doi: 10.1038/leu.2015.46. Epub 2015 Feb 23.

11.

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.

Weisberg E, Nonami A, Griffin JD.

Arch Toxicol. 2014 Dec;88(12):2233-42. doi: 10.1007/s00204-014-1385-5. Epub 2014 Oct 21. Review.

PMID:
25331939
12.

Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.

Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD.

Clin Cancer Res. 2014 Nov 1;20(21):5483-95. doi: 10.1158/1078-0432.CCR-14-0902. Epub 2014 Sep 3.

13.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.

Weisberg E, Nonami A, Chen Z, Liu F, Zhang J, Sattler M, Nelson E, Cowens K, Christie AL, Mitsiades C, Wong KK, Liu Q, Gray N, Griffin JD.

Leukemia. 2015 Jan;29(1):27-37. doi: 10.1038/leu.2014.149. Epub 2014 May 5.

14.

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.

Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24.

15.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.

PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21.

16.

Postinfarct cardiac free wall rupture detected by multidetector computed tomography.

Onoda N, Nonami A, Yabe T, Doi YL, Fujita Y, Yamamoto S, Ikebuchi M, Irie H.

J Cardiol Cases. 2012 Apr 18;5(3):e147-e149. doi: 10.1016/j.jccase.2012.03.004. eCollection 2012 Jun.

17.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.

18.

Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Matsuo Y, Kamezaki K, Takeishi S, Takenaka K, Eto T, Nonami A, Miyamoto T, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K.

Intern Med. 2009;48(16):1453-6. Epub 2009 Aug 17.

19.

Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient.

Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, Takenaka K, Miyamoto T, Harada N, Teshima T, Akashi K, Nagafuji K.

Int J Hematol. 2008 Oct;88(3):336-340. doi: 10.1007/s12185-008-0148-6. Epub 2008 Aug 19.

PMID:
18712461
20.

An unexpected cause of a febrile patient with huge splenomegaly.

Nonami A, Yamamoto H, Nakamura M, Nagafuji K, Teshima T.

Clin Rheumatol. 2008 Jul;27(7):941-3. doi: 10.1007/s10067-008-0856-6. Epub 2008 Mar 26.

PMID:
18365137
21.

Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.

Nonami A, Miyamoto T, Kuroiwa M, Kunisaki Y, Kamezaki K, Takenaka K, Harada N, Teshima T, Harada M, Nagafuji K.

Jpn J Clin Oncol. 2007 Dec;37(12):969-72. Epub 2007 Nov 30.

PMID:
18055567
22.

Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by up-front cord blood transplantation.

Nonami A, Takenaka K, Sumida C, Aizawa K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M.

Intern Med. 2007;46(20):1753-6. Epub 2007 Oct 15.

23.

Toxoplasmosis encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group.

Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, Kamezaki K, Tu L, Hisaeda H, Takenaka K, Harada N, Kamimura T, Ohno Y, Eto T, Teshima T, Gondo H, Harada M, Nagafuji K.

Eur J Haematol. 2007 Oct;79(4):317-21. Epub 2007 Aug 3.

PMID:
17680814
24.

Marked improvement of cardiac function early after non-myeloablative BMT in a heavily transfused patient with severe aplastic anemia and heart failure.

Kunisaki Y, Takase K, Miyamoto T, Fukata M, Nonami A, Kamezaki K, Kaji Y, Gondo H, Harada M, Nagafuji K.

Bone Marrow Transplant. 2007 Sep;40(6):593-5. Epub 2007 Jul 9. No abstract available.

PMID:
17618320
25.

Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis.

Nagafuji K, Nonami A, Kumano T, Kikushige Y, Yoshimoto G, Takenaka K, Shimoda K, Ohga S, Yasukawa M, Horiuchi H, Ishii E, Harada M.

Haematologica. 2007 Jul;92(7):978-81.

26.

Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Nonami A, Takenaka K, Kamezaki K, Miyamoto T, Harada N, Nagafuji K, Teshima T, Harada M.

Int J Hematol. 2007 Apr;85(3):264-6.

PMID:
17483065
27.

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.

Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, Aoki K, Kato K, Nonami A, Kamimura T, Arima F, Takenaka K, Harada N, Fukuda T, Hayashi S, Ohno Y, Eto T, Harada M, Nagafuji K.

Bone Marrow Transplant. 2007 May;39(9):523-7. Epub 2007 Mar 19.

PMID:
17369863
28.

Primary hepatic lymphoma 1 year after resection of hepatocellular carcinoma.

Nonami A, Takenaka K, Harada N, Kono K, Kamezaki K, Numata A, Karube K, Miyamoto T, Nagafuji K, Ohshima K, Harada M.

J Clin Oncol. 2006 Dec 20;24(36):5784-6. No abstract available.

PMID:
17179113
29.

The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1.

Nonami A, Taketomi T, Kimura A, Saeki K, Takaki H, Sanada T, Taniguchi K, Harada M, Kato R, Yoshimura A.

Genes Cells. 2005 Sep;10(9):887-95.

30.

Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia.

Taketomi T, Yoshiga D, Taniguchi K, Kobayashi T, Nonami A, Kato R, Sasaki M, Sasaki A, Ishibashi H, Moriyama M, Nakamura K, Nishimura J, Yoshimura A.

Nat Neurosci. 2005 Jul;8(7):855-7.

PMID:
15937482
31.

Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness.

Inoue H, Kato R, Fukuyama S, Nonami A, Taniguchi K, Matsumoto K, Nakano T, Tsuda M, Matsumura M, Kubo M, Ishikawa F, Moon BG, Takatsu K, Nakanishi Y, Yoshimura A.

J Exp Med. 2005 Jan 3;201(1):73-82.

32.

Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.

Nonami A, Kato R, Taniguchi K, Yoshiga D, Taketomi T, Fukuyama S, Harada M, Sasaki A, Yoshimura A.

J Biol Chem. 2004 Dec 10;279(50):52543-51. Epub 2004 Sep 30.

33.

Human herpes virus 8-negative primary effusion lymphoma (PEL) in a patient after repeated chylous ascites and chylothorax.

Nonami A, Yokoyama T, Takeshita M, Ohshima K, Kubota A, Okamura S.

Intern Med. 2004 Mar;43(3):236-42.

34.

Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.

Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A.

Cell Cycle. 2003 Jul-Aug;2(4):281-2. Review. No abstract available.

PMID:
12851472
35.

Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.

Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A.

Nat Cell Biol. 2003 May;5(5):427-32.

PMID:
12717443
36.

Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation.

Kato R, Nonami A, Taketomi T, Wakioka T, Kuroiwa A, Matsuda Y, Yoshimura A.

Biochem Biophys Res Commun. 2003 Mar 21;302(4):767-72.

PMID:
12646235

Supplemental Content

Loading ...
Support Center